An analysis of almost 700,000 people with type 2 diabetes or obesity found that those prescribed Ozempic or Wegovy were about half as likely to develop cannabis use disorder as those taking other medications
An analysis of almost 700,000 people with type 2 diabetes or obesity found that those prescribed Ozempic or Wegovy were about half as likely to develop cannabis use disorder as those taking other medications An analysis of almost 700,000 people with type 2 diabetes or obesity found that those prescribed Ozempic or Wegovy were about half as likely to develop cannabis use disorder as those taking other medications